Key Takeaways
- • TA Associates invests in AIRS Medical to fuel global expansion of the Seoul-based radiology AI firm, which processes 6 million MRI exams annually across 1,700+ healthcare institutions in 40+ countries, though deal terms remain undisclosed with closing expected by end of June 2026.
- • SwiftMR flagship technology reduces MRI scan times by approximately 45% on average while improving image quality through deep-learning noise removal post-acquisition, directly addressing radiology staffing shortages and capacity constraints driving institutional demand.
- • AIRS Medical builds on prior funding momentum: the company closed a $20 million Series C round in 2024 with participation from South Korean investors Shinyoung Securities and BSK Investment, signaling sustained capital appetite for medical imaging AI solutions.
- • TA Associates, managing $65 billion in capital since 1968, cites market tailwinds including radiology staffing gaps, growing exam volumes, and AIRS' competitive differentiation as rationale for the investment, positioning the firm to capitalize on operational efficiency demands across healthcare systems.
- • Product portfolio expansion underway: beyond SwiftMR, AIRS offers SwiftSight for consistent brain volumetry quantification across different MRI manufacturers and field strengths, with continued R&D planned post-investment.
Summary
TA Associates, a Boston-based global private equity firm, announced on June 16, 2026, a strategic investment in AIRS Medical, a Seoul-based artificial intelligence company specializing in MRI imaging optimization. The investment supports AIRS Medical's next phase of international expansion, though the firms did not disclose financial terms. TA indicated the transaction is expected to close by end of June 2026, subject to customary conditions.
Founded in 2018, AIRS Medical has achieved significant operational scale prior to this investment. The company currently supports over 1,700 healthcare institutions globally, processing 6 million MRI exams annually across more than 40 countries. This market penetration reflects strong adoption of its core offering, SwiftMR, a deep-learning platform that reduces MRI scan times while maintaining or improving diagnostic image quality. According to the company, SwiftMR achieves an average imaging time reduction of approximately 45% by applying deep learning post-acquisition to remove noise and blur without altering the underlying scan data.
The investment reflects broader private equity interest in medical imaging technology amid structural pressures within radiology departments. Edward Sippel, managing director and head of TA Asia Pacific, emphasized that AIRS Medical's "strong foundation and growing international presence" position it well to address "increasing demand for solutions that improve imaging efficiency, patient access and diagnostic consistency." These demand drivers align with well-documented radiology staffing shortages and rising exam volumes across healthcare systems globally.
AIRS Medical's capital-raising activity accelerated in 2024 when the company closed a $20 million Series C funding round led by South Korean investors Shinyoung Securities and BSK Investment, demonstrating sustained institutional interest in the radiology AI sector. The company's product ecosystem extends beyond SwiftMR to include SwiftSight, which targets consistent brain volumetry and quantification independent of MRI manufacturer or field strength. Following the TA Associates investment, AIRS Medical plans to advance existing AI-powered solutions and develop new offerings to deepen its competitive moat in the rapidly evolving medical imaging technology market.
Founded in 2018, AIRS Medical has achieved significant operational scale prior to this investment. The company currently supports over 1,700 healthcare institutions globally, processing 6 million MRI exams annually across more than 40 countries. This market penetration reflects strong adoption of its core offering, SwiftMR, a deep-learning platform that reduces MRI scan times while maintaining or improving diagnostic image quality. According to the company, SwiftMR achieves an average imaging time reduction of approximately 45% by applying deep learning post-acquisition to remove noise and blur without altering the underlying scan data.
The investment reflects broader private equity interest in medical imaging technology amid structural pressures within radiology departments. Edward Sippel, managing director and head of TA Asia Pacific, emphasized that AIRS Medical's "strong foundation and growing international presence" position it well to address "increasing demand for solutions that improve imaging efficiency, patient access and diagnostic consistency." These demand drivers align with well-documented radiology staffing shortages and rising exam volumes across healthcare systems globally.
AIRS Medical's capital-raising activity accelerated in 2024 when the company closed a $20 million Series C funding round led by South Korean investors Shinyoung Securities and BSK Investment, demonstrating sustained institutional interest in the radiology AI sector. The company's product ecosystem extends beyond SwiftMR to include SwiftSight, which targets consistent brain volumetry and quantification independent of MRI manufacturer or field strength. Following the TA Associates investment, AIRS Medical plans to advance existing AI-powered solutions and develop new offerings to deepen its competitive moat in the rapidly evolving medical imaging technology market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.